HARLOW, United Kingdom & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Argenta Discovery Ltd., the contract research and Respiratory R & D company, and Zafgen, Inc., a private venture-backed biopharmaceutical company focused on developing novel obesity therapeutics, today announced that they have entered into a major drug discovery collaboration. Under the terms of the agreement, scientists from the two companies will exploit Argenta’s expertise in computer-aided drug design, medicinal chemistry, assay development, in vitro screening, drug metabolism and pharmacokinetics to accelerate development candidate nomination for one of Zafgen’s innovative therapeutics programs for obesity.
